CN112956695A - 一种燕麦β-葡聚糖组合物及其制备方法和应用 - Google Patents
一种燕麦β-葡聚糖组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN112956695A CN112956695A CN202110365211.5A CN202110365211A CN112956695A CN 112956695 A CN112956695 A CN 112956695A CN 202110365211 A CN202110365211 A CN 202110365211A CN 112956695 A CN112956695 A CN 112956695A
- Authority
- CN
- China
- Prior art keywords
- parts
- glucan
- oat beta
- oligosaccharide
- oat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002498 Beta-glucan Polymers 0.000 title claims abstract description 71
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000012141 concentrate Substances 0.000 claims abstract description 41
- 239000000843 powder Substances 0.000 claims abstract description 33
- 244000046052 Phaseolus vulgaris Species 0.000 claims abstract description 24
- 240000000249 Morus alba Species 0.000 claims abstract description 23
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 23
- 235000014441 Prunus serotina Nutrition 0.000 claims abstract description 21
- 241001412173 Rubus canescens Species 0.000 claims abstract description 21
- 229920001353 Dextrin Polymers 0.000 claims abstract description 20
- 239000004375 Dextrin Substances 0.000 claims abstract description 20
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 20
- 235000019425 dextrin Nutrition 0.000 claims abstract description 20
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims description 22
- 239000008187 granular material Substances 0.000 claims description 15
- 235000013376 functional food Nutrition 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000011812 mixed powder Substances 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 244000013123 dwarf bean Species 0.000 claims description 4
- 235000021278 navy bean Nutrition 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 37
- 239000008280 blood Substances 0.000 abstract description 37
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 18
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 14
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 8
- 230000001603 reducing effect Effects 0.000 abstract description 8
- 235000012000 cholesterol Nutrition 0.000 abstract description 7
- 201000001421 hyperglycemia Diseases 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 108010022197 lipoprotein cholesterol Proteins 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 235000007319 Avena orientalis Nutrition 0.000 description 55
- 244000075850 Avena orientalis Species 0.000 description 55
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 241000209094 Oryza Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 235000013312 flour Nutrition 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 235000021391 short chain fatty acids Nutrition 0.000 description 5
- 150000004666 short chain fatty acids Chemical class 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 230000036186 satiety Effects 0.000 description 3
- 235000019627 satiety Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 101710171801 Alpha-amylase inhibitor Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 244000007021 Prunus avium Species 0.000 description 2
- 235000010401 Prunus avium Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000003392 amylase inhibitor Substances 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 235000021196 dietary intervention Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 108091005995 glycated hemoglobin Proteins 0.000 description 2
- 238000009478 high shear granulation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 208000005452 Acute intermittent porphyria Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241001290151 Prunus avium subsp. avium Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000010275 acute porphyria Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000295 fuel oil Substances 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000444 normolipidemic effect Effects 0.000 description 1
- 235000013348 organic food Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Agronomy & Crop Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种燕麦β‑葡聚糖组合物及其制备方法和应用,包括原料:燕麦β‑葡聚糖25‑50份,白芸豆粉12‑35份,桑葚浓缩物10‑30份,黑樱桃浓缩物10‑30份,α‑低聚半乳糖4‑12份,低聚木糖3‑10份,抗性糊精3‑10份。本发明通过将配方中各组分合理配伍组合,达到了协同增效作用,制备得到的燕麦β‑葡聚糖组合物具有显著的改善高血糖、高血脂的有益效果,对于血脂边缘升高、血糖边缘升高的人群亦有效,可显著降低血糖,降低血浆总胆固醇和低密度脂蛋白胆固醇(LDL‑C),降低心血管疾病风险,解决了单一组分降血糖、降血脂的功能性较弱的问题。
Description
技术领域
本发明属于功能食品或保健品食品技术领域,具体涉及一种燕麦β-葡聚糖组合物及其制备方法和应用。
背景技术
糖尿病和包括高血脂在内的心血管疾病发病率非常高,严重威胁着人类健康。虽然糖尿病和高血脂均有种类繁多的药物,但疾病的预防和治疗无法完全依靠药物实现,生活方式和饮食干预也有着重要作用。例如,糖尿病综合管理的“五驾马车”包括药物治疗、血糖检测、运动治疗、饮食治疗和患者教育,其中饮食治疗是基础。现代生活节奏快、压力大,而我国的饮食习惯又是重油重盐,因此健康生活方式和饮食干预经常受阻,这也造成了我国心血管疾病和糖尿病高发的现状。因此,十分有必要研发一种能够改善高血糖、高血脂的新型功能食品。
燕麦是唯一上榜“全球十大健康食物”的谷物类,1997年美国食药监局(FDA)认定燕麦具有降低胆固醇、平稳血糖的功效。燕麦中主要的功效成分是燕麦β-葡聚糖,是一种天然的β-1,3-/1,4-葡聚糖,具有特定的分子链结构、分子量和生理功效,与其他β-葡聚糖不同。
我国已于2014年批准燕麦β-葡聚糖为新食品原料。欧洲食品***(EFSA)声称每天食用3克以上燕麦β-葡聚糖,可降低低密度脂蛋白胆固醇(LDL-C),维持血脂正常水平;食用4克以上燕麦β-葡聚糖可降低餐后血糖。2014年被美国FDA批准为GRAS(一般安全食品),被许添加到有机食品中,因其降低冠心病风险、降低餐后血糖等功效,以及良好的安全性。
现有技术中大多是将燕麦β-葡聚糖与分散剂或矫味剂等简单混合制备而成,但单一组分的降血糖、降血脂的功能性较弱,因此,寻求新的食品资源,与燕麦β-葡聚糖合理配伍,开发具有明显改善高血糖、高血脂的功效的功能食品成为行业内的热点。
发明内容
为了克服上述现有技术的不足,本发明的目的在于提供一种燕麦β-葡聚糖组合物,该组合物中各组分协同增效,具有明显改善高血糖、高血脂的功效,可作为糖尿病、高血脂预防和治疗的饮食干预产品。
本发明是通过以下技术方案实现;
一种燕麦β-葡聚糖组合物,包括如下重量份数的原料:
燕麦β-葡聚糖25-50份,白芸豆粉 12-35份,桑葚浓缩物10-30份,黑樱桃浓缩物10-30份,α-低聚半乳糖4-12份,低聚木糖3-10份,抗性糊精3-10份。
作为进一步优选的技术方案,所述的一种燕麦β-葡聚糖组合物,各原料重量份为:
燕麦β-葡聚糖30-45份,白芸豆粉 15-30份,桑葚浓缩物12-25份,黑樱桃浓缩物12-25份,α-低聚半乳糖5-10份,低聚木糖4-8份,抗性糊精4-8份。
本发明各原料药理研究如下:
燕麦β-葡聚糖为提取自燕麦的天然β-1,3-/1,4-葡聚糖,一方面可以在肠道中吸水膨胀形成胶状物,减缓葡萄糖的吸收,增加饱腹感;另一方面可以与肠道中的胆汁酸相结合,促进胆固醇***,降低血浆中的胆固醇;另外燕麦β-葡聚糖可被肠道菌群利用,发酵生成丙酸、丁酸等短链脂肪酸,通过特殊信号通路改善改善胰岛素分泌等人体代谢机能,从而改善血糖和血脂异常升高等代谢性疾病。
白芸豆粉为豆科植物多花菜豆(拉丁学名Phaseolus vulgaris L.)的籽粒制成的豆粉,含有约10%的不溶性膳食纤维、23%的蛋白质和57%的碳水化合物,能够提供一定的饱腹感和能量,本身就是一种较为理想的代餐食品;另外白芸豆含有天然的α-淀粉酶抑制剂,可抑制淀粉在肠道内的分解和吸收,对于降低血糖具有协同作用。
桑葚浓缩物为桑科植物桑树(拉丁学名Morus alba Linn.)的成熟果实压榨浓缩加工而成的膏状物或粉末,含有大量的花青素,具有强大的抗氧化作用,可清除自由基,保护心血管的弹性,减少血脂斑块的形成,预防心血管疾病。
黑樱桃浓缩物为蔷薇科植物欧洲甜樱桃(拉丁学名Cerasus avium (L.)Moench.)的深色果实去籽后浓缩加工而成的膏状物或粉末,能够抑制炎症反应,促进血液循环,对于保护心血管、预防心血管疾病具有协同效应;另外黑樱桃还能够抑制尿酸生成、促进尿酸***,缓解痛风和关节炎,对糖尿病患者常见的高尿酸血症具有改善作用。
抗性糊精、α-低聚半乳糖和低聚木糖三者均属于益生元,能够改善肠道菌群、改善代谢、调节血糖和血脂。
本发明组合物以燕麦β-葡聚糖为基础成分,加入白芸豆粉、桑葚浓缩物、黑樱桃浓缩物三种主要辅助成分,燕麦β-葡聚糖能够延缓餐后血糖升高、增加饱腹感,另外通过菌群发酵产生短链脂肪酸(SCFAs)调节胰高血糖素样肽-1(GLP-1)等受体。白芸豆粉含有天然的α-淀粉酶抑制剂,可抑制淀粉在肠道内的分解和吸收。糖尿病与炎症反应有关,桑葚浓缩物、黑樱桃浓缩物可通过抑制炎症因子,改善胰岛素抵抗和分泌缺陷,各功效组分协同作用起到良好的降血糖效果。燕麦β-葡聚糖能够促进胆酸***,降低血浆胆固醇,另外通过菌群发酵产生短链脂肪酸调节脂代谢。白芸豆粉通过其膳食纤维降低胆固醇。血脂代谢异常和动脉硬化也是一种炎症反应,燕麦β-葡聚糖通过SCFAs受体使促炎因子基因表达下调,桑葚浓缩物、黑樱桃浓缩物均可抑制炎症因子,减少血脂斑块的形成,降低心血管病风险。另外桑葚浓缩物还具有清除自由基的功效,可保护心血管的弹性,预防心血管疾病。因此,各功效组分协同作用也起到良好的降血脂效果。抗性糊精、α-低聚半乳糖和低聚木糖作为益生元,可改善肠道益生菌,产生更丰富种类的SCFAs,起到改善代谢,调节血糖、血脂的作用。本发明组合物通过多组分协同作用,可以实现“1+1大于2”的互补增强效应。
本发明所述的改善高血糖、高血脂的燕麦β-葡聚糖组合物的制备方法有两种,分别对应粉剂和颗粒剂两种形式。
制备方法1(粉剂),包括如下步骤:
(1)将白芸豆粉与桑葚浓缩物、黑樱桃浓缩物混合均匀,得预混物A;
(2)将抗性糊精、α-低聚半乳糖、低聚木糖三者混合均匀,得预混物B;
(3)将燕麦β-葡聚糖先与预混物A混合均匀,再与预混物B混合均匀,即得燕麦β-葡聚糖组合物。
制备方法2(颗粒剂),包括如下步骤:
(1)将燕麦β-葡聚糖、白芸豆粉、抗性糊精、α-低聚半乳糖、低聚木糖混合均匀,得干混粉,备用;
(2)将桑葚浓缩物、黑樱桃浓缩物加适量水溶解成浓溶液;
(3)以步骤(2)所得的浓溶液作为粘合剂,与步骤(1)所得的干混粉,以湿法制粒工艺制备成颗粒,烘干去除水分,整粒,即得燕麦β-葡聚糖组合物。
步骤(3)所述的湿法制粒工艺包括但不限于高剪切制粒、流化床制粒、摇摆式制粒、挤出-滚圆制粒工艺。
两种制备方法对应的粉剂和颗粒剂在功效和用途上相同,只是在物理性状上有所不同。制备方法2(颗粒剂)中需要加入适量水分,但最终通过干燥将水分除去。
本发明所述的燕麦β-葡聚糖组合物的制备方法,还可以在粉剂或颗粒剂中添加胶态二氧化硅等抗结剂、助流剂,以改善制剂的物理性质,这属于同类制剂的常规工艺手段。
作为本发明所述的燕麦β-葡聚糖组合物的制备方法的延伸,上述组合物亦可加水溶解制备成液态制剂。加水溶解可在制备成粉剂或颗粒剂之后进行,亦可直接将各个组分溶解、混悬于水中。这属于常规的工艺处理手段,并不会改变本发明的功效和用途。
本发明还提供了上述的燕麦β-葡聚糖组合物在制备预防或治疗糖尿病或高血脂的功能食品、保健品或药品中的应用。
本发明还提供一种功能食品,包含上述的燕麦β-葡聚糖组合物及食品学上了可接受的辅料。所述辅料可以为各种香精、甜味剂、稳定剂等食品助剂,通过食品领域常规的技术手段制备即可。
优选地,所述功能食品的剂型为粉剂、颗粒剂或液态制剂。
本发明与现有技术相比,具有如下有益效果:
本发明提供一种燕麦β-葡聚糖组合物,包括燕麦β-葡聚糖,白芸豆粉,桑葚浓缩物,黑樱桃浓缩物等功效成分,通过将配方中各组分合理配伍组合,达到了协同增效作用,制备得到的燕麦β-葡聚糖组合物具有显著的改善高血糖、高血脂的有益效果,对于血脂边缘升高、血糖边缘升高的人群亦有效,可显著降低血糖,降低血浆总胆固醇和低密度脂蛋白胆固醇(LDL-C),降低心血管疾病风险,解决了单一组分降血糖、降血脂的功能性较弱的问题。
本发明作为一种功能食品,可融入到人们的日常饮食中,无不良反应,对于高血糖、高血脂可起到预防和辅助治疗的效果。
具体实施方式
下面通过具体实施方式来进一步说明本发明,以下实施例为本发明具体的实施方式,但本发明的实施方式并不受下述实施例的限制。
本发明实施例所采用的原料均来源于市购。
实施例1:
原料配比(重量份):
燕麦β-葡聚糖35份,白芸豆粉18份,桑葚浓缩物16份,黑樱桃浓缩物15份,α-低聚半乳糖6份,低聚木糖5份,抗性糊精5份。
制备方法:
将白芸豆粉与桑葚浓缩物、黑樱桃浓缩物混合均匀,得预混物A;将抗性糊精、α-低聚半乳糖、低聚木糖三者混合均匀,得预混物B;将燕麦β-葡聚糖先与预混物A混合均匀,再与预混物B混合均匀,即得燕麦β-葡聚糖组合物(粉剂)。
实施例2:
原料配比(重量份):
燕麦β-葡聚糖30份,白芸豆粉25份,桑葚浓缩物12份,黑樱桃浓缩物15份,α-低聚半乳糖6份,低聚木糖6份,抗性糊精6份。
制备方法:
将燕麦β-葡聚糖、白芸豆粉、抗性糊精、α-低聚半乳糖、低聚木糖混合均匀,得干混粉,备用;将桑葚浓缩物、黑樱桃浓缩物加适量水溶解成浓溶液;步骤(1)所得的干混粉置于湿法混合制粒机中,以步骤(2)所得的浓溶液作为粘合剂,以高剪切湿法制粒工艺制备成颗粒,干燥除去水分,整粒,即得改善燕麦β-葡聚糖组合物(颗粒剂)。
实施例3:
原料配比(重量份):
燕麦β-葡聚糖40份,白芸豆粉 20份,桑葚浓缩物15份,黑樱桃浓缩物 10份,α-低聚半乳糖5份,低聚木糖5份,抗性糊精5份。
制备方法同实施例1。
对比例1:
原料配比(重量份):
燕麦β-葡聚糖35份,米粉49份,α-低聚半乳糖6份,低聚木糖5份,抗性糊精5份。
制备方法:
将抗性糊精、α-低聚半乳糖、低聚木糖三者混合均匀,得预混物;将燕麦β-葡聚糖先与米粉混合均匀,再与预混物混合均匀,即得燕麦β-葡聚糖组合物。
对比例2:
原料配比(重量份):
燕麦β-葡聚糖35份,白芸豆粉18份,米粉31份,α-低聚半乳糖6份,低聚木糖5份,抗性糊精5份。
制备方法:
将白芸豆粉与米粉混合均匀,得预混物A;将抗性糊精、α-低聚半乳糖、低聚木糖三者混合均匀,得预混物B;将燕麦β-葡聚糖先与预混物A混合均匀,再与预混物B混合均匀,即得燕麦β-葡聚糖组合物。
通过人体试食数据进一步阐述本发明组方的有益效果。
试验方法:
轻度高胆固醇血症伴血糖异常者40例。随机分为4组,每组10例。
纳入标准:
(1)男女不限,年龄18~70岁。
(2)血糖异常史>2年,自行饮食控制或口服降糖药物且近期无药物调整者。
(3)轻度高胆固醇血症伴血糖异常者(包括糖尿病和糖耐量异常),即符合以下情况之一者:
1、TC(总胆固醇):5.2≤TC<6.2 mmol/L;
2、LDL-C(低密度脂蛋白胆固醇):3.4≤LDL-C<4.1mmol/L;
3、5.2≤TC<6.2mmol/L且3.4≤LDL-C<4.1mmol/L。
并且符合以下情况之一者:
1、FPG(空腹血糖)≥7.0 mmol/L,或OGTT(口服葡萄糖耐量试验)2h PG(2小时血糖)≥11.1 mmol/L;
2、FPG:6.1-6.9 mmol/L,或OGTT(2h PG):7.8-11.1 mmol/L。
排除标准:
(1)患者正接受降脂药物治疗或正接受胰岛素治疗。
(2)继发原因所致高脂血症者,如肾病综合征、甲状腺功能减退症、肾功能衰竭、肝脏疾病、***性红斑狼疮、糖原累积症、骨髓瘤、脂肪萎缩症、急性卟啉病、***等。
(3)对燕麦、白芸豆、其他豆类、桑葚、樱桃有过敏史者。
(4)妊娠及哺乳期妇女。
(5)使用利尿剂、非心脏选择性β受体阻滞剂、糖皮质激素等可能引起继发性血脂异常的患者。
干预措施:
40例符合标准的研究对象随机分为4组,每组10人,如下:
试验组:给予实施例1所述组合物10g/天;
对比组1:给予对比例1所述组合物10g/天;
对比组2:给予对比例2所述组合物10g/天;
对照组:给予安慰剂(米粉10g/天)。
所有样品均于每天早餐前以150mL温水冲调后顿服,研究期为8周。
所有组遵循相同的生活方式管理措施。
观察指标:
研究前及研究开始后4周和8周检测如下生化指标:
血脂:总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C);
血糖:空腹血糖(FPG)、糖化血红蛋白(HbA1c)。
试验结果如下表1-3所示:
表1:0天试验组、对比组1、对比组2、对照组四组基线生化指标数据:
四组之间的基线指标均无显著差异(P>0.1)。
表2:8周时四组生化指标数据:
表3:四组生化指标8周与0天差值:
以0-8周差值为评价指标,试验组分别与另外三组横向对比,统计结果如下:
试验组与对比组1相比:LDL-C、FPG两项指标有显著差异(P<0.01),HbA1c亦有显著差异(P<0.05);而TC、HDL-C、TG差异不显著(P>0.1);
试验组与对比组2相比:FPG和HbA1c均有显著差异(P<0.01),TC和LDL-C亦有显著差异(P<0.05);而TG差异不显著(P>0.1)。
试验组与对照组相比:TC、LDL-C、FPG、HbA1c均有显著差异(P<0.01),而HDL-C、TG差异不显著(P>0.1)。
结果表明,试验组(本发明组合物实施例1)与对比组1、2相比,具有显著的降低血浆胆固醇、空腹血糖和糖化血红蛋白HbA1c的优势;而试验组与对照组(阴性对照)相比,这种优势更明显。
此结果提示,本发明组合物将燕麦β-葡聚糖与白芸豆粉、桑葚浓缩物和黑樱桃浓缩物等形成配伍,具有增强的降血脂、降血糖功效,其有益效果优势明显,各组分实现了协同增强的效果。
Claims (7)
1.一种燕麦β-葡聚糖组合物,其特征在于,包括如下重量份数的原料:
燕麦β-葡聚糖25-50份,白芸豆粉 12-35份,桑葚浓缩物10-30份,黑樱桃浓缩物 10-30份,α-低聚半乳糖4-12份,低聚木糖3-10份,抗性糊精3-10份。
2.根据权利要求1所述的一种燕麦β-葡聚糖组合物,其特征在于,各原料重量份为:
燕麦β-葡聚糖30-45份,白芸豆粉 15-30份,桑葚浓缩物12-25份,黑樱桃浓缩物 12-25份,α-低聚半乳糖5-10份,低聚木糖4-8份,抗性糊精4-8份。
3.根据权利要求1或2所述的一种燕麦β-葡聚糖组合物的制备方法,其特征在于,包括如下步骤:
(1)将白芸豆粉与桑葚浓缩物、黑樱桃浓缩物混合均匀,得预混物A;
(2)将抗性糊精、α-低聚半乳糖、低聚木糖三者混合均匀,得预混物B;
(3)将燕麦β-葡聚糖先与预混物A混合均匀,再与预混物B混合均匀,即得燕麦β-葡聚糖组合物。
4.根据权利要求1或2所述的一种燕麦β-葡聚糖组合物的制备方法,其特征在于,包括如下步骤:
(1)将燕麦β-葡聚糖、白芸豆粉、抗性糊精、α-低聚半乳糖、低聚木糖混合均匀,得干混粉,备用;
(2)将桑葚浓缩物、黑樱桃浓缩物加适量水溶解成浓溶液;
(3)以步骤(2)所得的浓溶液作为粘合剂,与步骤(1)所得的干混粉,以湿法制粒工艺制备成颗粒,烘干去除水分,整粒,即得燕麦β-葡聚糖组合物。
5.权利要求1或2所述的燕麦β-葡聚糖组合物在制备预防或治疗糖尿病或高血脂的功能食品、保健品或药品中的应用。
6.一种功能食品,包含权利要求1或2所述的燕麦β-葡聚糖组合物及食品学上了可接受的辅料。
7.根据权利要求6所述的功能食品,其特征在于,所述功能食品的剂型为粉剂、颗粒剂或液态制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110365211.5A CN112956695A (zh) | 2021-04-06 | 2021-04-06 | 一种燕麦β-葡聚糖组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110365211.5A CN112956695A (zh) | 2021-04-06 | 2021-04-06 | 一种燕麦β-葡聚糖组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112956695A true CN112956695A (zh) | 2021-06-15 |
Family
ID=76281123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110365211.5A Pending CN112956695A (zh) | 2021-04-06 | 2021-04-06 | 一种燕麦β-葡聚糖组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112956695A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114521657A (zh) * | 2022-03-01 | 2022-05-24 | 珠海津之敦医药科技有限公司 | 一种谷物β-葡聚糖共蒸发复合物及其制备方法和应用 |
CN114532539A (zh) * | 2022-01-21 | 2022-05-27 | 翁源广业清怡食品科技有限公司 | 具有良好速溶性的粒状燕麦β-葡聚糖及其加工方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105595351A (zh) * | 2015-08-14 | 2016-05-25 | 广东省农业科学院蚕业与农产品加工研究所 | 一种具有稳态化调控血糖的营养产品及其制备方法和应用 |
CN106901367A (zh) * | 2017-03-14 | 2017-06-30 | 张勇 | 一种平衡血糖的组合物以及制备方法和用途 |
CN108523134A (zh) * | 2018-05-04 | 2018-09-14 | 珠海津之敦医药科技有限公司 | 一种燕麦β-葡聚糖口服组合物及其应用 |
CN110292175A (zh) * | 2019-08-06 | 2019-10-01 | 深圳远近健康科技有限公司 | 具有降血糖及减脂塑身功效的组合物及其生产方法和应用 |
-
2021
- 2021-04-06 CN CN202110365211.5A patent/CN112956695A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105595351A (zh) * | 2015-08-14 | 2016-05-25 | 广东省农业科学院蚕业与农产品加工研究所 | 一种具有稳态化调控血糖的营养产品及其制备方法和应用 |
CN106901367A (zh) * | 2017-03-14 | 2017-06-30 | 张勇 | 一种平衡血糖的组合物以及制备方法和用途 |
CN108523134A (zh) * | 2018-05-04 | 2018-09-14 | 珠海津之敦医药科技有限公司 | 一种燕麦β-葡聚糖口服组合物及其应用 |
CN110292175A (zh) * | 2019-08-06 | 2019-10-01 | 深圳远近健康科技有限公司 | 具有降血糖及减脂塑身功效的组合物及其生产方法和应用 |
Non-Patent Citations (3)
Title |
---|
向伟: "《儿童保健知识问答》", 31 October 2008, 中国医药科技出版社 * |
徐光来: "《轻松控制慢性病》", 31 October 2019, 浙江工商大学出版社 * |
秋风叶未落: "抑风清痛风管家:黑樱桃还有这种效果,痛风患者快来get新技能哦", 《搜狐》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114532539A (zh) * | 2022-01-21 | 2022-05-27 | 翁源广业清怡食品科技有限公司 | 具有良好速溶性的粒状燕麦β-葡聚糖及其加工方法 |
CN114532539B (zh) * | 2022-01-21 | 2024-05-10 | 翁源广业清怡食品科技有限公司 | 具有良好速溶性的粒状燕麦β-葡聚糖及其加工方法 |
CN114521657A (zh) * | 2022-03-01 | 2022-05-24 | 珠海津之敦医药科技有限公司 | 一种谷物β-葡聚糖共蒸发复合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103238897B (zh) | 一种适用于糖尿病人的复合植物固体饮料 | |
CN102406860B (zh) | 预防和治疗糖尿病的组合物、其制备方法及应用 | |
CN102273621B (zh) | 一种预防和治疗糖尿病的食品或保健食品 | |
CN106616187A (zh) | 一种辅助降三高的固体饮料 | |
CN108720030B (zh) | 一种靶向改善代谢综合征的膳食纤维组合物 | |
CN106360310A (zh) | 一种降低餐后血糖的组合物及其应用 | |
CN109221898A (zh) | 一种含低聚木糖的谷物粉及其制备方法和应用 | |
CN112956695A (zh) | 一种燕麦β-葡聚糖组合物及其制备方法和应用 | |
CN112741320A (zh) | 一种减肥组合物及其制备方法和应用 | |
CN110693028A (zh) | 一种降糖减脂组合物 | |
CN107212256A (zh) | 一种具有降血糖功能的代餐粉及其制备方法 | |
CN106858621A (zh) | 一种调节血糖血脂的膳食纤维组合物及其制备方法 | |
EP3978009A1 (en) | Traditional chinese medicine increase and decrease prescription for preventing/treating metabolic syndrome and complications thereof | |
CN113397094A (zh) | 一种降脂降糖大豆蛋白粉及其制备方法 | |
CN108450941A (zh) | 一种调节脂代谢的膳食组合物 | |
CN114532544A (zh) | 降糖、控糖的谷果植物肽固体饮料 | |
CN112535729B (zh) | 一种具有防治透析患者并发症功效的组合物及其制备方法和其应用 | |
WO1999053936A1 (en) | Hypoglycemic agents | |
CN113598372A (zh) | 一种用于干预高血糖的组合物及其制备方法 | |
Laksmitawati et al. | Activity of porang flour and moringa extract to blood glucose and lipid levels in alloxan induced diabetic mice | |
CN113826887A (zh) | 降压降脂降血糖营养粉、植物提取物及其应用 | |
CN108379455B (zh) | 一种降尿酸组合物 | |
CN112205617A (zh) | 一种适宜糖尿病及需要控制血糖人群食用的膳食 | |
CN111165813A (zh) | 一种辅助减肥与调控血糖的主食粉 | |
WO2024040630A1 (zh) | 一种控制血糖的组合物和制备方法及其在降低食物gi值中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210615 |
|
RJ01 | Rejection of invention patent application after publication |